Company Analysis CStone Pharmaceuticals
1. Summary
Advantages
- The stock's return over the last year (168.52%) is higher than the sector average (-43%).
Disadvantages
- Price (2.9 HK$) is higher than fair price (2.13 HK$)
- Dividends (0%) are below the sector average (5.6%).
- Current debt level 17.23% has increased over 5 years from 0.1457%.
- The company's current efficiency (ROE=-81.05%) is lower than the sector average (ROE=4.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| CStone Pharmaceuticals | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.1% | 0.4% | -1.9% |
| 90 days | 30% | -40% | -1.8% |
| 1 year | 168.5% | -43% | 32.2% |
2616 vs Sector: CStone Pharmaceuticals has outperformed the "Healthcare" sector by 211.52% over the past year.
2616 vs Market: CStone Pharmaceuticals has outperformed the market by 136.37% over the past year.
Stable price: 2616 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 2616 with weekly volatility of 3.24% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (2.9 HK$) is higher than the fair price (2.13 HK$).
Price is higher than fair: The current price (2.9 HK$) is 26.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.87).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (26.88).
4.3. P/BV
P/BV vs Sector: The company's P/BV (5.54) is higher than that of the sector as a whole (2.54).
P/BV vs Market: The company's P/BV (5.54) is higher than that of the market as a whole (1.66).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.46) is lower than that of the sector as a whole (6.25).
P/S vs Market: The company's P/S indicator (5.46) is higher than that of the market as a whole (2.66).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.24) is lower than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.24) is lower than that of the market as a whole (9.93).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -13.98% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-13.98%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-25.07%).
5.4. ROE
ROE vs Sector: The company's ROE (-81.05%) is lower than that of the sector as a whole (4.24%).
ROE vs Market: The company's ROE (-81.05%) is lower than that of the market as a whole (3.92%).
5.5. ROA
ROA vs Sector: The company's ROA (-22.25%) is lower than that of the sector as a whole (3.29%).
ROA vs Market: The company's ROA (-22.25%) is lower than that of the market as a whole (3.34%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '5.6%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
